Premium
Insulin‐like growth factor‐1 (IGF‐1) is a biomarker of objective cognitive impairment but not subjective cognitive complaint in cerebral palsy
Author(s) -
Ng Ted Kheng Siang,
Tagawa Alex,
Carollo James,
Heyn Patricia C.
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.046716
Subject(s) - cognition , biomarker , wechsler adult intelligence scale , effects of sleep deprivation on cognitive performance , cognitive decline , psychology , medicine , clinical psychology , audiology , dementia , oncology , psychiatry , disease , biochemistry , chemistry
Background Cognitive impairments are common in cerebral palsy (CP), however the evidence on the biological underpinnings of these impairments in CP has been scarce. Although insulin‐like growth factor‐1 (IGF‐1) is involved in cognitive deficits, its roles in cognitive functions in CP is unknown. We aimed to examine whether IGF‐1 is a biomarker of objective and self‐reported cognitive functions in CP. Method Based on a priori screening criteria, we recruited 72 adults with CP for a cross‐sectional study conducted in an accredited clinical motion analysis laboratory at Children’s Hospital Colorado. Subtests of the Wechsler Adult Intelligence Scale (WAIS) were administered to assess multiple cognitive functions. We used The Patient‐Reported Outcomes Measurement Information System (PROMIS) to measure multiple domains of self‐reported health, including cognitive complaints. Biomarkers were measured by fasting blood tests. All biomarkers measured were log‐transformed to conform to statistical normality. Result CP patients recruited had mean age=20 (SD=5.3), Male=47.2% and female=52.8%. Controlling for covariates, IGF‐1 correlated significantly with multiple cognitive domains, including delayed recall and recognition (declarative memory), block design (visual‐spatial and motor skills), and symbol search (processing speed). Furthermore, IGF‐1 correlated significantly with two other biomarkers, IL‐6 and IGF‐BP3, suggesting a network of insulin signaling and inflammatory biomarkers contributing to the objective cognitive impairment in multiple domains in CP patients. No association was found with subjective memory complaint, although IGF‐1 associated significantly with social roles and activities and physical function domains of PROMIS. Conclusion In CP patients, IGF‐1 is a useful biomarker for objective cognitive impairment and other self‐reported functions, but not subjective cognitive complaint.